제휴제안

CONTACT US [개인정보처리방침]
RESEARCH

연구개발

네오젠TC의 연구 및 성과를 확인해보세요.

파이프라인

Platform Project Theraqeutics Indication R&D Preclinical Phase I Phase II NDA
TIL NEOG-100 TIL
(Tumor Infiltrating Lymphocyte)
Solid tumor
(TNBC, NSCLC)
TCR-T NEOG-3000 Shared antigen specfic
TCR engineered T (TCR-T) cell
Solid tumor
TCR-T NEOG-4000 Private Neoantigen specific
TCR engineered T (TCR-T) cell
Solid tumor
TCR-T Transposon system Gene engineering system
  • NEOG-100

    • Theraqeutics

      TIL
      (Tumor Infiltrating Lymphocyte)
    • Indication

      Solid tumor
      (TNBC, NSCLC)
    • R&D
    • Preclinical
    • Phase I
    • Phase II
    • NDA
  • Transposon system

    • Theraqeutics

      Gene engineering system
    • Indication

    • R&D
    • Preclinical
    • Phase I
    • Phase II
    • NDA
  • NEOG-3000

    • Theraqeutics

      Shared antigen specfic
      TCR engineered T (TCR-T) cell
    • Indication

      Solid tumor
    • R&D
    • Preclinical
    • Phase I
    • Phase II
    • NDA
  • NEOG-4000

    • Theraqeutics

      Private Neoantigen specific
      TCR engineered T (TCR-T) cell
    • Indication

      Solid tumor
    • R&D
    • Preclinical
    • Phase I
    • Phase II
    • NDA